a Prospective Random Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer
Latest Information Update: 07 Jun 2022
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Docetaxel
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 04 Nov 2019 New trial record